Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27886320 | 0.81 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL12482759 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL13572985 | 0.80 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL7200197 | 0.79 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL1458716 | 0.79 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL6771873 | 0.77 | EDNRA (0.58) | — | |
| SCHEMBL9144126 | 0.77 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL10258693 | 0.77 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL14316697 | 0.76 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL27590195 | 0.76 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313953-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| CN-116891463-A | Heterocyclic compounds as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022200785-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
| CN-102816126-A | Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof | UNIV CHINA PHARMA | 2012-12-12 | — | — | CN | disclosed |
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | ALDH1A1 3595/4885SMN1; SMN2 4394/4885MAPT 3164/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | ALDH1A1 4115/4885SMN1; SMN2 4272/4885MAPT 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.